新的数据显示 ,Ｏｘｉｇｅｎｅ公司正在进行试验的药物ｃｏｍｂｒｅｔａｓｔａｔｉｎＡ4前体药 (ＣＡ4Ｐ)和放射免疫疗法一起使用时 ,能够消除 85 %长瘤小鼠的肿瘤达到 9个月以上。伦敦皇家医学院的科学家认为 ,ＣＡ4Ｐ能够明显提高放射免疫疗法治疗肿瘤的效果 ,提高长期治愈率 New data show that Oxigene’s drug combretastatin A4 prodrug (CA4P), used in conjunction with radioimmunotherapy, is able to eliminate tumors in 85% of tumor-bearing mice for more than nine months. Scientists at the Royal College of London believe that CA4P can significantly improve the effectiveness of radioimmunotherapy in the treatment of tumors and improve the long-term cure rate